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INTRODUCTION 
The size of elderly population is increasing rapidly worldwide, 
and according to data from Statistics Korea in 2016, people 
aged 65 years and older accounted for 13.6% of the entire Ko-
rean population. Cardiovascular (CV) diseases are a leading 
cause of death in elderly people, and it presents various chal-
lenges in both diagnosis and treatment.1 The management of 
elderly patients with CV diseases differs from the management 
of younger patients with the same diseases.2 In order to better 
define treatment and predict prognosis, it is more important 
to determine the exercise capacity in elderly patients than that 
in younger patients. 
Cardiopulmonary exercise testing (CPET) is an exercise 
stress test with concomitant expired gas analysis, which pro-
vides objective parameters of functional capacity. Since CPET 
can assess integrated exercise responses of cardiopulmonary, 
vascular, and skeletomuscular systems,3 it can reveal abnor-
malities that are not apparent in a resting state. Current clinical 
indications of CPET are used to define the cause of dyspnea/
exercise intolerance, establish the severity of advanced cardiac 
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disease, determine cardiac intervention in valvular/congeni-
tal heart disease, and precisely evaluate the functional re-
sponse to an intervention.4 CPET is also useful in the assess-
ment of preoperative risk and prediction of postoperative CV 
outcomes.5 Therefore, risk assessment using CPET in elderly 
patients with CV diseases is becoming more important. 
Nonetheless, many Korean physicians are unwilling to per-
form exercise stress testing, especially in elderly patients with 
CV diseases. Their reasons include: 1) concerns regarding the 
risk of an adverse event during CPET; 2) unavailability of CPET 
equipment; 3) lack of awareness about the importance of eval-
uating exercise capacity; and 4) preference for evaluating car-
diac function over performing exercise capacity assessment.
Previous studies demonstrated the safety of CPET for people 
with CV diseases such as heart failure (HF), coronary artery 
disease, and cardiac transplantation. The 2002 American Heart 
Association exercise testing guidelines cite an adverse event 
rate of up to 0.04% or 1 per 2500 tests.6 CPET has been shown to 
be safe in HF patients with severe systolic dysfunction.7 Even 
in patients with underlying high-risk CV diseases, CPET is gen-
erally a safe procedure with a 0.16% total adverse event rate.8 
CV disease in the elderly population has been considered a 
contraindication to exercise testing, albeit with a lack of data 
about CPET safety. 
As cardiac rehabilitation becomes more common, demand 
for CPET has increased in Korea. However, large-scale data on 
CPET values for Koreans with CV disease are lacking. There-
fore, we examined the characteristics and safety of CPET in a 
large, heterogeneous population of elderly Korean patients 
with underlying CV diseases.
MATERIALS AND METHODS 
Study population 
This was a cross-sectional, observational, single-center cohort 
study. We reviewed records of 10300 patients who underwent 
CPET between July 2011 and March 2016 at the Cardiac Well-
ness Center of Severance Cardiovascular Hospital. We defined 
older patients as being 65 years in age or older, excluding 
those aged <65 years (n=7508). Patients without definite CV 
disease (n=638) and those who underwent CPET for routine 
medical check-up (n=21) were excluded. We also excluded 
patients who only had hypertension (HTN) without other CV 
disease (n=648). A total of 1485 patients ≥65 years with CV 
disease who underwent CPET were identified. We included 
data on patients who underwent CPET multiple times during 
the study period. Demographic characteristics including age, 
sex, body mass index, and medical history including HTN, di-
abetes mellitus, chronic kidney disease, dyslipidemia, and cere-
brovascular attack were reviewed. HTN was defined as previ-
ous diagnosis or systolic blood pressure (BP) >140 mm Hg or 
diastolic BP >90 mm Hg by repeated BP measurements. CV 
diseases were categorized as: ischemic heart disease (IHD), 
HF, valvular heart disease (VHD), hypertrophic cardiomyopa-
thy (HCMP), and congenital heart disease. IHD was defined 
as myocardial infarction, unstable angina, and stable angina 
that had significant coronary artery stenosis (luminal narrow-
ing ≥70%) with or without coronary artery bypass graft or per-
cutaneous coronary intervention. HF was identified by review-
ing medical records for patients with B-type natriuretic peptide 
(BNP) greater than 35 pg/mL or N-terminal pro-BNP levels 
greater than 125 pg/mL and echocardiography favorable for 
HF.9 VHD was diagnosed and graded through echocardiogram 
according to 2014 AHA/ACC guidelines.10 Diagnosis of HCMP 
was determined by echocardiography based on presence of 
myocardial hypertrophy without local or systemic etiologies.11 
Obstructive HCMP was defined as left ventricular outflow 
tract (LVOT) peak instantaneous Doppler gradient ≥30 mm Hg 
upon resting or when provoked with the Valsalva maneuver. 
Non-obstructive HCMP was defined as both a resting and pro-
voked gradient of <30 mm Hg.12 This study was approved by 
the ethics committee of Severance Hospital, Seoul, South Korea 
(IRB No. 4-2016-1087), and written informed consent was 
waived due to the retrospective nature of this study.
Cardiopulmonary exercise testing
All CPET was performed by specialist nurses certified by the 
American College of Sports Medicine and supervised by a sin-
gle cardiologist. Before tests, patients were assessed for resting 
BP, heart rate (HR), and echocardiographic results, including 
left ventricular ejection fraction. Patients with ongoing chest 
pain at rest, pulmonary edema on chest X-ray, hypotension, 
significant bradycardia/tachycardia, or significant ST changes 
>0.05 mV at resting electrocardiography (ECG) were prohibit-
ed from undergoing the test. All patients underwent CPET ac-
cording to the modified Bruce ramp protocol using two motor-
driven treadmills (Exercise Testing System®, GE Healthcare, 
Chicago, IL, USA). For expired gas collection and analysis, the 
Quark CPET (COSMED, Rome, Italy) was used. CPET was per-
formed by monitoring 12-lead ECG, manual BP measure-
ments, and HR at every stage. Total test time was 16 minutes 
40 seconds, and recovery time was at least 5 minutes. Speed 
and grade were increased every 20 seconds. All patients were 
encouraged to perform a submaximal, symptom-limited test. 
Termination criteria were patient request, ventricular arrhyth-
mia [ventricular tachycardia (VT) or ventricular fibrillation], 
or horizontal or downsloping ST depression of ≥1 mm Hg dur-
ing exercise. Peak respiratory exchange ratio (RER), exercise 
duration, lactate threshold (LT) time, peak oxygen uptake (peak 
VO2), metabolic equivalents of task (METs), dead space/tidal 
volume (VD/VT) ratio, partial pressure of end-tidal carbon di-
oxide, minute ventilation-carbon dioxide output relationship 
(VE/VCO2 slope), peak systolic BP, peak HR, HR reserve, and 
HR recovery were measured automatically. Peak VO2 was de-
fined as the highest VO2 value achieved during exercise.
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Interpretation and adverse events of 
cardiopulmonary exercise testing
All CPET results with exercise ECG were interpreted by the 
supervising cardiologist. A 1.0-mm horizontal or downsloping 
ST-segment depression 0.08 seconds after J-point in the ab-
sence of significant resting ST-T abnormalities, pre-excitation, 
ventricular pacing, digitalis, or left bundle branch block was 
considered a positive finding for ischemia. Exercise effort qual-
ity was assessed by RER, which was calculated using the for-
mula VCO2/VO2.
According to a previous study on CPET safety,8 we defined 
adverse events for CPET as: 1) death during the stress test, 2) 
external defibrillation or implantable cardioverter-defibrilla-
tor discharge, 3) sustained VT (wide complex tachycardia last-
ing longer than 30 seconds), 4) myocardial infarction, 5) synco-
pe, 6) administration of advanced cardiac life support medications, 
7) referral for direct hospital admission, or 8) referral to emer-
gency department.
Statistical analysis 
Statistical analyses were performed with SPSS 18.0 for Windows 
(SPSS Inc., Chicago, IL, USA). Data normality was tested using 
the Kolmogorov-Smirnov test. Values are expressed as means 
(±SD) for numerical variables or as number of participants 
and their percentages for categorical variables. Continuous 
variables were compared using the Student’s t-test and ANO-
VA test. Analysis of categorical data was performed using the 
chi-square test. Two-tailed p<0.05 was considered statistically 
significant. 
 
 
RESULTS
We analyzed CPET data on 1485 patients. The mean age was 
71.6±4.7 years, with 567 patients aged 60–65 years, 818 patients 
aged 70–79 years, and 100 patients aged 80–89 years (Fig. 1). 
Among them, 154 patients underwent CPET multiple times 
(two times: 129 patients; three times: 21 patients; four times: 4 
patients). Baseline clinical characteristics and categories of 
CV diseases are presented in Table 1. In the categories of CV 
diseases, IHD was the most common (60.9%), followed by HF 
(25.1%). Among 82 patients with HCMP, 18 had hemodynam-
ically LVOT obstruction. Among patients with VHD, 47 had 
severe VHD and mitral regurgitation was most common. 
CPET results are shown in Table 2. For overall patients, mean 
RER was 1.09±0.14 with 268 (18.0%) with RER <1.0. Mean 
peak VO2 was 21.35±5.5 mL/kg/min, mean METs was 6.1±1.6 
and mean exercise duration was 568.5±203.2 seconds. Men 
showed better exercise capacity than women (peak VO2, 22.5± 
5.9 vs. 19.7±4.5 mL/kg/min, p<0.001; exercise time 600.4±210.1 
vs. 512.1±177.1 sec, p<0.001). Comparing CPET results by age 
group showed a significant difference in exercise capacity 
(65–69 vs. 70–79 vs. 80–89: peak VO2, 22.9±5.8 vs. 20.7±5.1 vs. 
17.0±4.5 mL/kg/min, p<0.001; VE/VCO2 slope, 32.9±5.8 vs. 
34.0±6.1 vs. 37.9±7.0, p<0.001) (Table 3). When we analyzed 
exercise capacity according to age grouped by sex, METs were 
Fig. 1. Flow diagram of study population. CPET, cardiopulmonary exercise 
test; CV, cardiovascular.
Patients performed CPET from
July 2011 to March 2016 (n=10300)
Age <65 years (n=7508)
Patients without CV disease (n=638)
Medical check up (n=21)
Patients with only hypertension (n=648)
Age ≥65 years (n=2792)
Patients with CV disease
(n=2133)
Analyzed (n=1485)
Age 65–69 (n=567)
Age 70–79 (n=818)
Age 80–89 (n=100)
Table 1. Baseline Clinical Characteristics
Characteristic n=1485
Age (yr) 71.6±4.7
Male, n (%) 949 (63.9)
Height (cm) 161.8±8.8
Body weight (kg) 63.8±10.4
Body mass index (kg/m2) 24.4±4.9
Comorbidity (%)
Hypertension 66.9
Diabetes mellitus 37.2
Dyslipidemia 47.9
Stroke 7.8
Chronic kidney disease 6.3
Cardiovascular disease
Ischemic heart disease, n (%) 905 (60.9)
Heart failure, n (%) 372 (25.1)
Congenital heart disease, n (%) 23 (1.5)
Hypertrophic cardiomyopathy, n (%) 82 (5.5)
 Obstructive, n 18
 Non-obstructive, n 64
Valvular heart disease, n (%) 103 (6.9)
 Severe aortic stenosis, n 11
 Severe aortic regurgitation, n 10
 Severe mitral regurgitation, n 26
 Severe mitral stenosis, n 0
Values are presented as mean±SD or number (percentage) unless otherwise 
noticed.
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significantly reduced as age increased in both men and wom-
en (Fig. 2). CPET results for patients of all ages who under-
went CPET at our center during the same period are in Sup-
plementary Table 1 (only online). 
A total of three adverse cardiovascular events were noted 
during CPET for all patients. All events were sustained VT with 
spontaneous recovery to sinus rhythm without electrical car-
dioversion. Among the patients, two had dilated cardiomyop-
athy and one had IHD (Table 4).
Reasons for termination of CPET are shown in Fig. 3A. Only 
45 patients (3.0%) completed CPET according to the protocol 
with no patients aged ≥80 years. Dyspnea was the most com-
mon cause, and leg discomfort was the second most common 
cause, accounting for 64.8% and 24.3%, respectively. Leg pain 
was significantly higher in octogenarians than other groups 
(65–69 vs. 70–79 vs. 80–89: 22.4% vs. 24.6% vs. 32.0%, p<0.001) 
(Fig. 3B). 
DISCUSSION
This study found a lower adverse event rate (0.20%) in a large, 
elderly population. Previously, the Mayo Clinic reported 0.16% 
adverse events in high-risk CV patients and patients older 
than 65 years showed similar event rate (0.16%).8 We had fewer 
high-risk patients than in the Mayo Clinic study, but our pop-
Table 2. CPET Results of the Population
CPET parameters Total (n=1485) Male (n=949) Female (n=536) p value 
Exercise duration (sec) 568.5±203.2 600.4±210.1 512.1±177.1 <0.001
Peak VO2 (mL/kg/min) 21.3±5.5 22.2±5.9 19.7±4.5 <0.001
METs 6.1±1.6 6.3±1.7 5.6±1.3 <0.001
RER 1.09±0.14 1.09±0.11 1.08±0.18 0.047
LT time (sec) 307.6±191.3 334.2±193.8 260.5±177.4 <0.001
VD/VT 0.31±0.04 0.32±0.04 0.30±0.04 <0.001
PetCO2 (mm Hg) 36.5±6.0 36.2±5.3 36.9±6.5 0.018
VE/VCO2 slope 33.8±6.3 34.4±6.6 32.8±5.14 <0.001
Baseline SBP (mm Hg) 123.5±17.7 122.5±18.4 125.4±16.4 0.002
Peak SBP (mm Hg) 180.3±32.1 179.6±33.4 181.5±29.6 0.270
Baseline HR (bpm) 69.6±13.1 69.7±13.5 69.6±12.6 0.927
Peak HR (bpm) 129.2±23.3 129.4±23.6 128.9±22.7 0.668
CPET, cardiopulmonary exercise test; peak VO2, peak oxygen uptake; METs, metabolic equivalents of task; RER, respiratory exchange ratio; LT, lactate threshold; 
VD/VT, dead space/tidal volume ratio; PetCO2, end tidal carbon dioxide; VE/VCO2 slope, minute ventilation-carbon dioxide output relationship; SBP, systolic blood 
pressure; HR, heart rate.
All values are presented as mean±SD. 
Table 3. Comparison of CPET Results according to Age Group
CPET parameters 65–69 (n=567) 70–79 (n=818) 80–89 (n=100) p value (ANOVA)
Mean age (yr) 67.1±1.4 73.3±2.5* 82.7±2.6*† <0.001
Male (%) 66.3 61.7 68.0 0.148
Exercise time (sec) 619.8±210.2 553.0±188.7* 404.5±168.9*† <0.001
Peak VO2 (mL/kg/min) 22.9±5.8 20.7±5.1* 17.0±4.5*† <0.001
METs 6.5±1.6 5.9±1.5* 4.8±1.3*† <0.001
RER 1.11±0.18 1.08±0.11* 1.03±0.10*† <0.001
LT time (sec) 344.9±191.2 293.9±188.7* 208.1±162.7*† <0.001
VD/VT 0.30±0.04 0.31±0.04* 0.33±0.05*† <0.001
PetCO2 (mm Hg) 36.8±5.0 36.6±6.2* 33.1±5.2*† <0.001
VE/VCO2 slope 32.9±5.8 34.0±6.1* 37.9±7.0*† <0.001
Baseline SBP (mm Hg) 122.6±17.9 124.0±17.7 125.2±17.5 0.216
Peak SBP (mm Hg) 182.0±33.8 180.4±30.9 169.9±30.1*† 0.003
Baseline HR (bpm) 69.8±13.1 69.6±12.8 69.3±15.9 0.898
Peak HR (bpm) 134.3±23.2 127.6±22.1* 114.1±24.8*† <0.001
CPET, cardiopulmonary exercise test; peak VO2, peak oxygen uptake; METs, metabolic equivalents of task; RER, respiratory exchange ratio; LT, lactate threshold; 
VD/VT, dead space/tidal volume ratio; PetCO2, end tidal carbon dioxide; VE/VCO2 slope, minute ventilation-carbon dioxide output relationship; SBP, systolic blood 
pressure; HR, heart rate.
All values are presented as mean±SD. 
*p<0.05 vs. age 65–69 group, †p<0.05 vs. age 70–79 group.
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ulation contained some high-risk patients with severe VHD 
(n=46), HCMP (n=82), severely reduced LVEF (<30%) (n=71), 
and severely reduced functional capacity by peak VO2 <14 
mL/kg/min (n=142). Based on the statistics maintained at our 
center, among all age groups of 13031 patients who under-
went CPET, a total of eight adverse events occurred (total ad-
verse event rate 0.061%: seven cases were sustained VT, all self-
terminated the test, and one case was syncope followed by 
cardiac arrest during the recovery phase). All eight patients 
were aged under 70 years, suggesting that older age was not 
an absolute risk factor for CPET. Although there is a limit to 
present safety of CPET by statistically low values, it seems to 
be meaningful considering the number of patients in our data. 
Bicycle ergometers are widely used in CPET due to their low-
er cost, compact space requirements, and reduced noise level 
compared to a treadmill.13 A standard bicycle exercise ramp 
protocol is relatively safe for elderly patients with chronic HF.14 
However, bicycles have the limitation that leg fatigue can in-
duce early termination of a test, and peak VO2 is 10–20% lower 
in individuals not accustomed to cycling.15 In exercise proto-
cols using a treadmill, the Bruce protocol is most commonly 
used; however, it has the disadvantage of a large interstage 
workload increment between stages that can make estimation 
of peak VO2 less accurate.
13 Our center performed exercise 
tests using only the Bruce ramp protocol. This protocol is bet-
ter able to overcome sudden and rapid work rate changes, 
Fig. 2. Comparison of METs according to age group. Male (A) and female (B) patients. METs, metabolic equivalents of task.
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Table 4. Adverse Cardiovascular Events during CPET
Patients Diagnosis Peak VO2 (mL/kg/min) RER Adverse event
68 years, female Dilated cardiomyopathy 26.2 1.12 VT
65 years, male Dilated cardiomyopathy 23.3 1.24 VT
67 years, male Ischemic heart disease (CAOD 3VD) 33.6 1.41 VT
CPET, cardiopulmonary exercise test; peak VO2, peak oxygen uptake; RER, respiratory exchange ratio; CAOD, coronary artery obstructive disease; VT, ventricular 
tachycardia; 3VD, 3 vessel disease.
Adverse cardiovascular response 0.9%
Arrhythmia 0.5%
ST segment elevation/depression 0.2%
Exaggerated BP elevation/depression 0.2%
Others 1.5%
Fatigue 1.1%
Dizziness 1.7%
Chest pain 2.6%
Finish the test 3.0%
70
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30
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0
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Age groupReasons for test termination
Dyspnea                Leg pain
Leg pain
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Fig. 3. Reasons for CPET termination in overall population (A) and prevalence of dyspnea and leg pain for CPET termination according to age group (B). 
CPET, cardiopulmonary exercise test.
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and can more accurately assess exercise capacity than other 
exercise protocols.15 In particular, for HF reduced systolic func-
tion or IHD with large myocardial fibrosis, a sudden increment 
in workload may be associated with increased risk of sudden 
hypotension or ventricular arrhythmia. Although few studies 
compared risks of the Bruce ramp protocol with other exercise 
protocols, we believe that using the Bruce ramp protocol was 
a potential factor contributing to the lower incidence of ad-
verse events observed in our population.
Percutaneous valvular procedures, such as transcatheter 
aortic valve replacement (TAVR) or percutaneous mitral bal-
loon valvuloplasty, have been performed in even very old pa-
tients. In particular, TAVR procedure use has increased expo-
nentially in elderly patients with severe aortic stenosis, with 
technical advancement of the procedure and improvements 
in performance.16 Evaluating functional capacity precisely is 
important for determining if surgery is feasible in elderly pa-
tients with VHD. The tendency has been increasingly aggres-
sive treatment for elderly patients with VHD. Our findings 
support that CPET should be implemented in elderly patients 
with moderate to severe VHD for assessment of functional ca-
pacity. Physicians are also concerned about adverse events of 
CPET for people with HCMP. In HCMP with hemodynamic 
LVOT obstruction, exercise testing especially poses a risk of 
arrhythmia or hemodynamic collapse.6 However, previous 
studies showed the safety of CPET in HCMP17,18 and our data 
support this safety, with no adverse events occurring in people 
with HCMP. As CPET can provide important prognostic infor-
mation about patients with HCMP,17 it is considered a feasible 
test for elderly patients. 
In Korea, there is a lack of standard data on the exercise capac-
ity of elderly population with CV diseases. Our results showed 
that elderly Korean patients with CV diseases had an exercise 
capacity of about 6.1 METs, decreasing proportionally with in-
creasing age. Women had significantly poorer exercise capacity 
than men. Several parameters such as the mean age, peak VO2, 
and METs were comparable in our study with previous studies19 
or were higher than in other studies performed in older pa-
tients with CV diseases.8,14 Octogenarian men in our popula-
tion had 5.0±1.3 METs of exercise capacity, similar to American 
men older than 80 years without major CV disease.20 Consid-
ering our population had definite CV diseases compared to 
American patients in the abovementioned study, we suggest 
that our population had a relatively good exercise capacity. 
Therefore, our results meaningfully support that elderly Kore-
an patients with CV diseases can perform active cardiac reha-
bilitation. 
We found that leg pain was the second most common cause 
for termination of tests with increasing proportions according 
to age. Another report also showed that leg fatigue was the 
second most common cause of termination in elderly Korean 
people with coronary artery disease.21 Musculoskeletal fac-
tors, such as sarcopenia or joint disorders, are commonly as-
sociated with the elderly patients, and sarcopenia is closely 
associated with cardiorespiratory fitness in community-dwell-
ing elderly Koreans.22 In patients with CV diseases, especially 
in those with HF, most show dyspnea on exercise. The tended 
to refrain from physical activity that worsens sarcopenia; there-
fore, sarcopenia may have a greater effect on exercise capacity 
or quality of life than in elderly people without CV diseases. In 
addition, joint problems or back pain, and a deteriorating sense 
of balance can limit the accurate assessment of functional ca-
pacity and possibly increase the risk of falling in elderly pa-
tients.23 Although musculoskeletal or autonomic function de-
ficiencies due to aging are unavoidable, additional efforts are 
required to ensure exercise tests can be performed safely in el-
derly patients with limitations on physical activity. Novel equip-
ment such as bicycles tailored specifically to this population 
that allow exercising in a recumbent or supine position may be 
a useful modality to reduce these limitations.24
Our study had several limitations. First, it was a retrospec-
tive, single, tertiary referral center study. Second, we did not 
quantitatively assess pulmonary function. Deteriorated pul-
monary function may have affected the CPET results. Third, 
generalizing CPET values is difficult due to variations in CV 
disease and its severity. Fourth, since all patients had CPET us-
ing only the Bruce ramp protocol, there was a limitation in rep-
resenting the safety of all CPET modalities. Fifth, we could not 
evaluate the daily physical activity of patients, including leg 
muscle strength or power, which may have affected exercise 
capacity. Sixth, we did not analyze safety of CPET according to 
each CV disease.
However, to our knowledge, this is the first large-scale study 
to assess the safety and characteristics of CPET in elderly Ko-
rean patients with CV diseases. Considering our sample size, 
this study presents meaningful characteristics of CPET in el-
derly Korean patients with CV diseases. 
In conclusion, CPET is a relatively safe and useful modality 
to assess exercise capacity in elderly Korean patients with CV 
diseases. Further studies are warranted to validate the appli-
cation of CPET in this population.
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